ADC Therapeutics SA (NYSE:ADCT) Receives $6.25 Average Price Target from Brokerages

ADC Therapeutics SA (NYSE:ADCT – Get Free Report) has been assigned an average recommendation of “Hold” from the six ratings firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $6.25.

Several equities analysts have commented on ADCT shares. HC Wainwright lowered ADC Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, June 8th. Stephens reaffirmed an “overweight” rating and issued a $5.00 target price on shares of ADC Therapeutics in a research report on Thursday, June 4th. Cantor Fitzgerald reiterated an “overweight” rating on shares of ADC Therapeutics in a research note on Thursday, June 4th. Royal Bank Of Canada cut shares of ADC Therapeutics from an “outperform” rating to a “sector perform” rating and lowered their price target for the company from $6.00 to $2.00 in a research report on Thursday, June 4th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of ADC Therapeutics in a research note on Friday, July 17th.

Get ADC Therapeutics alerts:

View Our Latest Research Report on ADC Therapeutics

Institutional Trading of ADC Therapeutics

A number of hedge funds have recently made changes to their positions in ADCT. R Squared Ltd purchased a new stake in shares of ADC Therapeutics in the 1st quarter worth approximately $38,000. Engineers Gate Manager LP purchased a new position in ADC Therapeutics during the fourth quarter valued at $43,000. Quantinno Capital Management LP raised its stake in ADC Therapeutics by 36.0% during the first quarter. Quantinno Capital Management LP now owns 14,719 shares of the company’s stock valued at $55,000 after buying an additional 3,894 shares during the last quarter. ProShare Advisors LLC raised its stake in ADC Therapeutics by 27.0% during the fourth quarter. ProShare Advisors LLC now owns 15,727 shares of the company’s stock valued at $56,000 after buying an additional 3,339 shares during the last quarter. Finally, AXQ Capital LP bought a new stake in ADC Therapeutics in the fourth quarter worth $57,000. 41.10% of the stock is owned by institutional investors.

ADC Therapeutics Stock Up 2.0%

ADCT opened at $1.12 on Friday. The stock has a market cap of $142.71 million, a PE ratio of -1.07 and a beta of 1.87. The business has a 50 day moving average of $1.56 and a 200-day moving average of $3.07. ADC Therapeutics has a 52 week low of $0.78 and a 52 week high of $4.98.

ADC Therapeutics (NYSE:ADCT – Get Free Report) last released its quarterly earnings results on Monday, May 4th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.02). The company had revenue of $20.85 million during the quarter, compared to the consensus estimate of $19.99 million. During the same quarter in the previous year, the company earned ($0.36) EPS. Equities analysts anticipate that ADC Therapeutics will post -0.88 EPS for the current year.

About ADC Therapeutics

(Get Free Report)

ADC Therapeutics SA is a clinical-stage biopharmaceutical company focused on the discovery and development of highly targeted antibody-drug conjugates (ADCs) designed to treat hematological malignancies such as non-Hodgkin lymphoma and acute myeloid leukemia. By marrying the specificity of monoclonal antibodies with potent cytotoxic payloads, the company aims to maximize tumor cell eradication while limiting off-target toxicity.

At the core of ADC Therapeutics’ portfolio is loncastuximab tesirine-lpyl, a CD19-directed ADC that received accelerated approval from the U.S.

Featured Stories

• Five stocks we like better than ADC Therapeutics
• Microsoft Just Flipped the AI Spending Narrative Overnight
• Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
• Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
• Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes

Receive News & Ratings for ADC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.